Literature DB >> 33669517

Extracellular Vesicle-Derived microRNAs of Human Wharton's Jelly Mesenchymal Stromal Cells May Activate Endogenous VEGF-A to Promote Angiogenesis.

Cinzia Maria Chinnici1,2, Gioacchin Iannolo2, Ettore Cittadini3, Anna Paola Carreca1, David Nascari4, Francesca Timoneri1,2, Mariangela Di Bella1,2, Nicola Cuscino2, Giandomenico Amico1,2, Claudia Carcione1, Pier Giulio Conaldi2.   

Abstract

Despite low levels of vascular endothelial growth factor (VEGF)-A, the secretome of human Wharton's jelly (WJ) mesenchymal stromal cells (MSCs) effectively promoted proangiogenic responses in vitro, which were impaired upon the depletion of small (~140 nm) extracellular vesicles (EVs). The isolated EVs shared the low VEGF-A profile of the secretome and expressed five microRNAs, which were upregulated compared to fetal dermal MSC-derived EVs. These upregulated microRNAs exclusively targeted the VEGF-A gene within 54 Gene Ontology (GO) biological processes, 18 of which are associated with angiogenesis. Moreover, 15 microRNAs of WJ-MSC-derived EVs were highly expressed (Ct value ≤ 26) and exclusively targeted the thrombospondin 1 (THBS1) gene within 75 GO biological processes, 30 of which are associated with the regulation of tissue repair. The relationship between predicted microRNA target genes and WJ-MSC-derived EVs was shown by treating human umbilical-vein endothelial cells (HUVECs) with appropriate doses of EVs. The exposure of HUVECs to EVs for 72 h significantly enhanced the release of VEGF-A and THBS1 protein expression compared to untreated control cells. Finally, WJ-MSC-derived EVs stimulated in vitro tube formation along with the migration and proliferation of HUVECs. Our findings can contribute to a better understanding of the molecular mechanisms underlying the proangiogenic responses induced by human umbilical cord-derived MSCs, suggesting a key regulatory role for microRNAs delivered by EVs.

Entities:  

Keywords:  VEGF-A and THBS1 target genes; Wharton’s jelly; extracellular vesicles; in vitro angiogenesis; mesenchymal stromal cells; microRNAs

Mesh:

Substances:

Year:  2021        PMID: 33669517      PMCID: PMC7922033          DOI: 10.3390/ijms22042045

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  64 in total

1.  Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model.

Authors:  Sung-Whan Kim; Hoon Han; Gue-Tae Chae; Sung-Hoon Lee; Sun Bo; Jung-Hee Yoon; Yong-Soon Lee; Kwang-Soo Lee; Hwon-Kyum Park; Kyung-Sun Kang
Journal:  Stem Cells       Date:  2006-02-23       Impact factor: 6.277

Review 2.  miRNAs as modulators of angiogenesis.

Authors:  Shira Landskroner-Eiger; Isabelle Moneke; William C Sessa
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

Review 3.  The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles.

Authors:  Takeshi Katsuda; Nobuyoshi Kosaka; Fumitaka Takeshita; Takahiro Ochiya
Journal:  Proteomics       Date:  2013-02-26       Impact factor: 3.984

4.  MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells.

Authors:  Lei Fan; Qiang Wu; Xiaojuan Xing; Yulong Wei; Zengwu Shao
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2012-04-02       Impact factor: 3.848

5.  Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis.

Authors:  Na Wang; Caiyu Chen; Dezhong Yang; Qiao Liao; Hao Luo; Xinquan Wang; Faying Zhou; Xiaoli Yang; Jian Yang; Chunyu Zeng; Wei Eric Wang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-02-27       Impact factor: 5.187

6.  Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis.

Authors:  Rebecca A Dragovic; Christopher Gardiner; Alexandra S Brooks; Dionne S Tannetta; David J P Ferguson; Patrick Hole; Bob Carr; Christopher W G Redman; Adrian L Harris; Peter J Dobson; Paul Harrison; Ian L Sargent
Journal:  Nanomedicine       Date:  2011-05-04       Impact factor: 5.307

Review 7.  AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review).

Authors:  Yarely M Salinas-Vera; Laurence A Marchat; Dolores Gallardo-Rincón; Erika Ruiz-García; Horacio Astudillo-De La Vega; Raquel Echavarría-Zepeda; César López-Camarillo
Journal:  Int J Mol Med       Date:  2018-11-27       Impact factor: 4.101

Review 8.  MicroRNAs in skin and wound healing.

Authors:  Jaideep Banerjee; Chandan K Sen
Journal:  Methods Mol Biol       Date:  2013

9.  Comparison of Immunosuppressive and Angiogenic Properties of Human Amnion-Derived Mesenchymal Stem Cells between 2D and 3D Culture Systems.

Authors:  Vitale Miceli; Mariangela Pampalone; Serena Vella; Anna Paola Carreca; Giandomenico Amico; Pier Giulio Conaldi
Journal:  Stem Cells Int       Date:  2019-02-18       Impact factor: 5.443

10.  Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly.

Authors:  Paola Romina Amable; Marcus Vinicius Telles Teixeira; Rosana Bizon Vieira Carias; José Mauro Granjeiro; Radovan Borojevic
Journal:  Stem Cell Res Ther       Date:  2014-04-16       Impact factor: 6.832

View more
  2 in total

1.  Intraperitoneally Delivered Mesenchymal Stem Cells Alleviate Experimental Colitis Through THBS1-Mediated Induction of IL-10-Competent Regulatory B Cells.

Authors:  Jialing Liu; Xingqiang Lai; Yingying Bao; Wenfeng Xie; Zhishan Li; Jieying Chen; Gang Li; Tao Wang; Weijun Huang; Yuanchen Ma; Jiahao Shi; Erming Zhao; Andy Peng Xiang; Qiuli Liu; Xiaoyong Chen
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

2.  MicroRNA-Enriched Exosomes from Different Sources of Mesenchymal Stem Cells Can Differentially Modulate Functions of Immune Cells and Neurogenesis.

Authors:  Naina Soni; Suchi Gupta; Surender Rawat; Vishnu Krishnakumar; Sujata Mohanty; Arup Banerjee
Journal:  Biomedicines       Date:  2021-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.